• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Trinity Biotech plc

    2/28/25 8:30:40 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TRIB alert in real time by email
    6-K 1 zk2532784.htm 6-K


    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549
                                   

    FORM 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
     
    For the month of February 2025

    TRINITY BIOTECH PLC
    (Name of Registrant)

    IDA Business Park
    Bray, Co. Wicklow, Ireland
     (Address of Principal Executive Office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒    Form 40-F ☐      

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):          

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):          

    Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

    Yes ☐    No ☒

    If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-               

    This Form 6-K is being incorporated by reference into our Registration Statements on Form F-3 (File Nos. 333-267160, 333-279017, 333-280391, 333-283273) and Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).




     EXPLANATORY NOTE

    On February 27, 2025, Trinity Biotech plc and certain of its subsidiaries amended and restated the Credit Agreement and Guaranty agreement governing the companies’ term loan facility with Perceptive Credit Holdings III, L.P.



    EXHIBIT INDEX

    Exhibit
     
    Description
     
     
     
    99.1

    Fourth Amended and Restated Credit Agreement and Guaranty, dated as of February 27, 2025.
    99.2
     
    Trinity Biotech Announces Additional Funding to Support Transformation Plan & Continued Development of the Company’s Continuous Glucose Monitoring Technology.
     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     
    TRINITY BIOTECH PLC
     
       
    Trinity Biotech plc
     
       
    (Registrant)
     
           
     
    By:
    /s/ Louise Tallon
     
       
    Louise Tallon
     
       
    Chief Financial Officer
     

    Date:  February 28, 2025



    Get the next $TRIB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRIB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

      SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)

      11/14/24 5:26:28 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by Trinity Biotech plc (Amendment)

      SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)

      5/1/24 4:57:00 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D filed by Trinity Biotech plc

      SC 13D - TRINITY BIOTECH PLC (0000888721) (Subject)

      2/9/24 7:51:28 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $TRIB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update

      DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2024 and the fiscal year then ended. Key Highlights and Developments Management continues to make significant progress on the execution of the profitability focused initiatives announced in 2024 as part of its Comprehensive Transformation Plan, many of which are now completed or at the final stages of execution and expected to deliver near term profitability improvements: Consolidation & Offshore Manufacturing: We ob

      5/15/25 4:00:39 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement

      DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice today from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of US $1.00 per share, based on the closing bid price of the Company's American depositary shares ("ADSs") for the last 30 consecutive business days. The Company also received notice today that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed

      3/14/25 4:30:00 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

      DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring ("CGM") technology with the appointment of Barclays Capital Inc. ("Barclays") as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the Company's increased focus on its CGM technology as part of its broader transformation plan. With substantial progress in developing its differentiated and

      3/13/25 7:30:00 AM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $TRIB
    Leadership Updates

    Live Leadership Updates

    See more
    • Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

      DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring ("CGM") technology with the appointment of Barclays Capital Inc. ("Barclays") as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the Company's increased focus on its CGM technology as part of its broader transformation plan. With substantial progress in developing its differentiated and

      3/13/25 7:30:00 AM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer

      DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) --  Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Adrian Donohue as Chief Commercial Officer. Mr. Donohue brings more than 25 years of experience in the sales and marketing of healthcare products. John Gillard, President and Chief Executive Officer of Trinity Biotech, said, "We are resolute in continuing to execute on our transformation agenda, which will drive greater performance and profitability in our existing product lines, including supporting continued growth in our newest r

      9/3/24 9:55:00 AM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director

      DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appointment of David Ouston as Biosensor Marketing Director. Mr. Ouston brings a wealth of commercial experience driving the growth of glucose monitoring devices at large, established companies across global markets. John Gillard, President and Chief Executive Officer of Trinity Biotech, said, "We remain focused on our innovative, needle-free, reusable continuous glucose monitoring (CGM) technology as a key long-term growth driver for Trinity Biotech, and we

      8/20/24 5:00:00 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $TRIB
    SEC Filings

    See more
    • SEC Form 6-K filed by Trinity Biotech plc

      6-K - TRINITY BIOTECH PLC (0000888721) (Filer)

      5/15/25 4:17:20 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form NT 20-F filed by Trinity Biotech plc

      NT 20-F - TRINITY BIOTECH PLC (0000888721) (Filer)

      4/30/25 4:36:31 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 6-K filed by Trinity Biotech plc

      6-K - TRINITY BIOTECH PLC (0000888721) (Filer)

      4/4/25 8:39:18 AM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $TRIB
    Financials

    Live finance-specific insights

    See more
    • Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update

      DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2024 and the fiscal year then ended. Key Highlights and Developments Management continues to make significant progress on the execution of the profitability focused initiatives announced in 2024 as part of its Comprehensive Transformation Plan, many of which are now completed or at the final stages of execution and expected to deliver near term profitability improvements: Consolidation & Offshore Manufacturing: We ob

      5/15/25 4:00:39 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement

      DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice today from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of US $1.00 per share, based on the closing bid price of the Company's American depositary shares ("ADSs") for the last 30 consecutive business days. The Company also received notice today that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed

      3/14/25 4:30:00 PM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology

      DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has obtained an additional $4m in debt financing from its primary lender, Perceptive Advisors. The additional liquidity will support both the continued development of Trinity Biotech's innovative continuous glucose monitoring (CGM) technology and the Company's comprehensive transformation plan. The Company continues to focus much of its growth efforts around its CGM technology, especially given the previously announced positive results from its mos

      2/28/25 8:30:00 AM ET
      $TRIB
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care